Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells

European Journal of Pharmacology

Volumn 634, Issue 1-3, 2010, Pages 178-183

  Yoshida, Hiroto ^a   Hashizume, Misato ^a   Suzuki, Miho ^a   Mihara, Masahiko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anti interleukin 6 receptor antibody; Anti TNF antibody; Regulatory T cell; T cell activation

Indexed keywords

CD28 ANTIBODY; CD3 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 6 ANTIBODY; LYMPHOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; GROWTH INHIBITOR; INTERLEUKIN 6 RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FEMALE; IMMUNOREGULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CD4 LYMPHOCYTE COUNT; CELL CULTURE; CELL DIFFERENTIATION; COMPARATIVE STUDY; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; GROWTH INHIBITORS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; RECEPTORS, INTERLEUKIN-6; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 77951192680     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.026     Document Type: Article

References (17)

1. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
2. Chauhan D., Kharbanda S., Ogata A., Urashima M., Teoh G., Robertson M., Kufe D.W., Anderson K.C. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997, 89:227-234.
3. Chen R.H., Chang M.C., Su Y.H., Tsai Y.T., Kuo M.L. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem. 1999, 274:23013-23019.
4. Diehl S., Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 2002, 39:531-536.
5. Feldmann M., Brennan F.M., Williams R.O., Cope A.P., Gibbons D.L., Katsikis P.D., Maini R.N. Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. Prog. Growth Factor Res. 1992, 4:247-255.
6. Fox R.I., Fong S., Sabharwal N., Carstens S.A., Kung P.C., Vaughan J.H. Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. J. Immunol. 1982, 128:351-354.
7. Fujimoto M., Serada S., Mihara M., Uchiyama Y., Yoshida H., Koike N., Ohsugi Y., Nishikawa T., Ripley B., Kimura A., Kishimoto T., Naka T. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 2008, 58:3710-3719.
8. Hemler M.E., Glass D., Coblyn J.S., Jacobson J.G. Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation. J. Clin. Invest. 1986, 78:696-702.
9. Jee S.H., Shen S.C., Chiu H.C., Tsai W.L., Kuo M.L. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001, 20:198-208.
10. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991, 174:561-569.
11. Maini R., St.Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
12. Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Hashimoto J., Azuma J., Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004, 50:1761-1769.
13. Okazaki M., Yamada Y., Nishimoto N., Yoshizaki K., Mihara M. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol. Lett. 2002, 84:231-240.
14. Olsen N.J., Murray L.M. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum. 1989, 32:378-385.
15. Suzuki M., Hashizume M., Yoshida H., Mihara M. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol. Int. 2010, 30:309-315.
16. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., Jackson C.G., Lange M., Burge D.J. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 1999, 340:253-259.
17. Yoshimura N., Matsui S., Hamashima T., Oka T. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation 1989, 47:351-356.